Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Evaluation of Dual Antiplatelet Therapy Compliance and Outcomes After Treatment With the Xience Stent.

Next Previous
Trial Profile

Prospective Evaluation of Dual Antiplatelet Therapy Compliance and Outcomes After Treatment With the Xience Stent.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Antiplatelets; Aspirin; Clopidogrel
  • Indications Coronary artery disease; Stent thrombosis
  • Focus Adverse reactions
  • Acronyms PREDICT-X

Most Recent Events

  • 06 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
  • 03 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
  • 11 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top